Ultragenyx Pharmaceutical Inc(RARE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:51 PM ET (Korea 9/11 08:51)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -5.84 | Insider Own | 8.79% | Shs Outstand | 98.3M | Perf Week | -45.72% |
| Market Cap | 1.42B | Forward P/E | - | EPS next Y | 82.48% | Insider Trans | -0.52% | Shs Float | 89.9M | Perf Month | -46.59% |
| Enterprise Value | 2.33B | PEG | - | EPS next Q | -0.87 | Inst Own | 105.34% | Short Float | 17.67% | Perf Quarter | -37.31% |
| Income | -0.59B | P/S | 1.98 | EPS this Y | 31.44% | Inst Trans | 1.01% | Short Ratio | 5.11 | Perf Half Y | -35.16% |
| Sales | 0.72B | P/B | - | EPS next 5Y | 71.02% | ROA | -45.63% | Short Interest | 15.89M | Perf YTD | -37.39% |
| Book/sh | -2.96 | P/C | 4.72 | EPS past 3/5Y | 16.78% -13.72% | ROE | -656.54% | 52W High | -63.9% ($39.89) | Perf Year | -53.98% |
| Cash/sh | 3.05 | P/FCF | - | Sales past 3/5Y | 22.81% 19.95% | ROIC | -70.23% | 52W Low | 4.27% ($13.81) | Perf 3Y | -65.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -5.66% | Gross Margin | 78.47% | Volatility(W/M) | 5.94% 4.72% | Perf 5Y | -85.84% |
| Dividend TTM | - | EV/Sales | 3.25 | Sales Y/Y TTM | 17.5% | Oper. Margin | -73.77% | ATR (14) | 1.78 | Perf 10Y | -78.32% |
| Dividend Ex-Date | - | Quick Ratio | 1.56 | EPS Q/Q | 22.67% | Profit Margin | -81.79% | RSI (14) | 20.37 | Recom | 2.05 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.73 | Sales Q/Q | 28.53% | SMA20 | -37.89% ($23.18) | Beta | 0.36 | Target Price | $25.74 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/4 | SMA50 | -46.04% ($26.69) | Rel Volume | 1.14 | Prev Close | $14.31 |
| Employees | 1371 | LT Debt/Eq | - | EPS/Sales Surpr. | 26.08% 16.89% | SMA200 | -44.05% ($25.74) | Avg Volume(3M) | 3.11M | Price | $14.4 |
| IPO | 2014/1/31 | Option/Short | Yes/Yes | Trades | 26315 | Volume | 3,531,141 | Change | 0.63% |
Company
RARE is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A U.S. biopharmaceutical company that develops and commercializes treatments for rare and ultra-rare genetic diseases. It has a diversified pipeline—including marketed products and gene therapies—targeting rare genetic diseases with high unmet need, and is building a differentiated position as a rare-disease-focused biopharma with deep expertise and a broad pipeline in the rare disease field.
Over the past 1 year, on the lower side
64% below its 1-year high.
RARE has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -65.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 105.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
TMFS 0.03%
GNOM 0.02%
HAPS 0.01%
XBI 0.01%
BBP 0.01%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
REMX 2.2B
REXC 71M
EART 46M
EMET 39M
FMTL 33MIt ranks #4 in the industry
Based on market cap of $1B.
RARE $1B PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is RARE?
RARE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RARE?
The market cap of RARE is approximately $1.4B, ranking 2,363 within its sector.
What is the 52-week high and low for RARE?
RARE has recorded a 52-week high of $39.89 and a low of $13.81.
